Safety, Tolerability and Pharmacokinetics of Tiotropium in Cystic Fibrosis Patients
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Study to obtain information about the safety and tolerability of tiotropium bromide
administered via the Respimat® inhalation device in pediatric (≤11 y.o.) and adolescent/adult
(≥12 y.o.) cystic fibrosis (CF) patients after single and multiple doses as well as to obtain
pharmacokinetic data for tiotropium in CF patients after single and multiple doses